Akari Therapeutics and Whitehawk Therapeutics are evaluating dual payload synergy for next generation Antibody-Drug Conjugate (ADC) development.
1 report, 1 independent
Updated Jul 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Akari Therapeutics and Whitehawk Therapeutics are evaluating dual payload synergy for next generation Antibody-Drug Conjugate (ADC) development.